QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-05 08:10 UTC · Public disclosure record

VRTXTICKER

Vertex Pharmaceuticals Inc. / Ma

BULLISH stock

Congress has disclosed 13 buys and 18 sells of VRTX (Vertex Pharmaceuticals Inc. / Ma) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

13
Buy
18
Sell
-5
Net
15
Active politicians

Round-trip watch Still on the books

Members who disclosed buying VRTX and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.

MemberEntry (last buy)Entry priceNowvs entryStatus
Alan Armstrong 2026-03-27 $433.07 $566.11 +30.7% in profit
Julia Letlow 2024-10-23 $470.05 $566.11 +20.4% in profit

Price as of 2026-11-02. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).

Price & congressional trades
Buy Sell

Fundamentals · FY2026 Valuation

Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.

P/E
36.1
▲ pricier than Health (median 29.7)
how it's calculated
P/E = price ÷ earnings per share
$566.11 ÷ $15.68 = 36.1
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
6.87
▲ pricier than Health (median 4.4)
how it's calculated
P/B = price ÷ book value per share
$566.11 ÷ $82.46 = 6.87
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
EV/EBITDA
31.69
▲ pricier than Health (median 16.2)
how it's calculated
EV/EBITDA = (market cap + net debt) ÷ EBITDA — net cash lowers EV
($143.5B − $0.5B net cash) ÷ $4.5B = $143.0B ÷ $4.5B = 31.69
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.

Legislation Related Legislation

Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.

BillTitlePolicy areaLatest action
HR 10887 Protecting Consumer Access to Generic Drugs Act of 2026 Health 2026-10-22
HR 10874 Medicare Low Income Subsidy Equality Act of 2026 Health 2026-10-22
HR 10858 CARE for Blood Cancer Act of 2026 Health 2026-10-22
HR 10810 National Patient Safety Board Act of 2026 Health 2026-10-15
HR 10824 Stroke Education and EMS Care Improvement Act of 2026 Health 2026-10-15

32 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

PoliticianChamberTypeOwnerDateDisclosure lagPrice move
in that
window
AmountScoreSource
David Taylor House SELL ◆ insider convergence Self · David Taylor Trust > Schwab Joint Brokerage #1 (Home Grown) 2026-08-26 8 days +1.9% $1K–$15K
0.3% of NW
53.7 ↗ filing
Alan Armstrong Senate BUY ◆ insider divergence Self 2026-03-27 116 days +11.3% $1K–$15K 99.1 ↗ eFD
David Taylor House SELL ◆ insider convergence Self · David Taylor Trust > Sardinia Ready Mix 401(k) - Dave 2026-01-29 1 days -1.2% $1K–$15K
0.3% of NW
29.6 ↗ filing
David Taylor House BUY ◆ insider convergence · strong Self · David Taylor Trust > Schwab Joint Brokerage #1 (Home Grown) 2025-08-07 12 days +4.0% $1K–$15K
0.3% of NW
64.7 ↗ filing
Lisa McClain House SELL ◆ insider divergence · strong Spouse · Charles Schwab Brokerage Account 924 2025-06-11 63 days -12.5% $1K–$15K
0.1% of NW
82.7 ↗ filing
Lisa McClain House SELL ◆ insider divergence · strong Spouse · Charles Schwab Brokerage Account 924 2025-06-10 64 days -12.3% $1K–$15K
0.1% of NW
89.5 ↗ filing
Jefferson Shreve House SELL ◆ insider convergence Self · CRT - Standard Unit Trust 2025-05-12 3 days -1.1% $15K–$50K
<0.1% of NW
53.7 ↗ filing
Byron Donalds House SELL ◆ insider convergence Self · Moran Wealth IRA 2025-03-20 18 days -7.0% $1K–$15K
0.3% of NW
64.8 ↗ filing
Byron Donalds House SELL ◆ insider convergence Spouse · Moran Wealth IRA 2025-03-20 18 days -7.0% $1K–$15K
0.3% of NW
64.8 ↗ filing
Jefferson Shreve House BUY ◆ insider divergence Self · CRT - Standard Unit Trust 2025-02-24 5 days -0.4% $15K–$50K
<0.1% of NW
69.2 ↗ filing
Lisa McClain House BUY ◆ insider divergence Spouse · Charles Schwab Brokerage Account 548 2024-12-11 243 days -20.0% $1K–$15K
0.1% of NW
97.3 ↗ filing
Julia Letlow House BUY ◆ insider divergence Self · Merrill Lynch Investment Account #025 2024-10-23 292 days -20.3% $1K–$15K
1.0% of NW
66.0 ↗ filing
Thomas Tuberville Senate OTHER Joint 2024-05-03 824 days — $1K–$15K 98.8 ↗ eFD
Greg Stanton House SELL ◆ insider convergence Spouse 2023-10-24 2 days — $1K–$15K
0.5% of NW
40.4 ↗ filing
Greg Stanton House BUY ◆ insider divergence Spouse 2023-09-26 25 days — $1K–$15K
0.5% of NW
75.9 ↗ filing
William Keating House BUY Self · Bill's IRA 2022-03-29 34 days — $1K–$15K
0.3% of NW
75.9 ↗ filing
Peter Meijer House SELL Self 2021-01-28 6 days — $1K–$15K 75.9 ↗ filing
Dean Phillips House BUY Self 2020-12-18 20 days — $1K–$15K
<0.1% of NW
75.9 ↗ filing
Josh Gottheimer House SELL Joint 2019-09-19 18 days — $1K–$15K
<0.1% of NW
8.6 ↗ filing
Donna Shalala House SELL Self 2019-06-24 6 days — $1K–$15K 40.4 ↗ filing
Donna Shalala House BUY Self 2019-04-18 12 days — $1K–$15K 75.9 ↗ filing
Josh Gottheimer House SELL Joint 2019-04-11 28 days — $1K–$15K
<0.1% of NW
10.6 ↗ filing
Gilbert Cisneros House SELL Self 2019-02-26 9 days — $15K–$50K
0.3% of NW
56.6 ↗ filing
Gilbert Cisneros House SELL Self 2019-01-31 13 days — $1K–$15K
0.1% of NW
75.9 ↗ filing
Josh Gottheimer House SELL Joint 2018-06-01 116 days — $1K–$15K
<0.1% of NW
15.7 ↗ filing
Josh Gottheimer House SELL Joint 2018-05-01 147 days — $1K–$15K
<0.1% of NW
22.3 ↗ filing
Josh Gottheimer House BUY Joint 2017-07-19 385 days — $1K–$15K
<0.1% of NW
40.4 ↗ filing
Josh Gottheimer House BUY Joint 2017-04-13 482 days — $1K–$15K
<0.1% of NW
75.9 ↗ filing
Thomas MacArthur House BUY Joint 2016-11-02 29 days — $1K–$15K 22.3 ↗ filing
Thomas MacArthur House BUY Joint 2016-11-01 30 days — $1K–$15K 40.4 ↗ filing
Michael Conaway House SELL Spouse 2016-09-12 3 days — $1K–$15K 75.9 ↗ filing
Thomas MacArthur House SELL Joint 2016-02-02 28 days — $1K–$15K 75.9 ↗ filing

Corporate insiders · SEC Form 4 Insider Activity

What the company's own officers and directors did in VRTX — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →

7
Congress trades with insider convergence
7
…with insider divergence
364
Insider open-market trades

Of the congressional trades in VRTX, 7 coincided with corporate insiders moving the same way within 60 days, and 7 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.

DateInsiderRoleTypeSizeSource
2026-07-02 McKechnie Duncan C-suite SELL 10b5-1 $800K ↗ EDGAR
2026-07-02 Tatsis Ourania C-suite SELL 10b5-1 $787K ↗ EDGAR
2026-07-01 Liu Joy C-suite SELL 10b5-1 $416K ↗ EDGAR
2026-06-26 Bozic Carmen Other SELL 10b5-1 $288K ↗ EDGAR
2026-06-18 Bozic Carmen Other SELL 10b5-1 $471K ↗ EDGAR
2026-06-15 Bozic Carmen Other SELL 10b5-1 $1.8M ↗ EDGAR
2026-06-05 Bozic Carmen Other SELL 10b5-1 $785K ↗ EDGAR
2026-06-01 Liu Joy C-suite SELL 10b5-1 $364K ↗ EDGAR
2026-05-29 Bozic Carmen Other SELL 10b5-1 $888K ↗ EDGAR
2026-05-15 Bozic Carmen Other SELL 10b5-1 $614K ↗ EDGAR
2026-05-15 Bunnage Mark E. C-suite SELL 10b5-1 $15K ↗ EDGAR
2026-05-12 Bozic Carmen Other SELL 10b5-1 $3.1M ↗ EDGAR
2026-05-04 Bhatia Sangeeta N. Director SELL 10b5-1 $135K ↗ EDGAR
2026-05-01 Liu Joy C-suite SELL 10b5-1 $469K ↗ EDGAR
2026-04-01 Liu Joy C-suite SELL 10b5-1 $439K ↗ EDGAR
2026-03-27 Bozic Carmen Other SELL 10b5-1 $1.1M ↗ EDGAR
2026-03-13 Bozic Carmen Other SELL 10b5-1 $1.1M ↗ EDGAR
2026-03-11 McKechnie Duncan C-suite SELL 10b5-1 $1.3M ↗ EDGAR
2026-03-04 McKechnie Duncan C-suite SELL 10b5-1 $1.2M ↗ EDGAR
2026-03-02 Liu Joy C-suite SELL 10b5-1 $442K ↗ EDGAR
2026-02-27 Bozic Carmen Other SELL 10b5-1 $1.1M ↗ EDGAR
2026-02-27 Kewalramani Reshma C-suite SELL 10b5-1 $192K ↗ EDGAR
2026-02-27 Kewalramani Reshma C-suite SELL 10b5-1 $58K ↗ EDGAR
2026-02-27 Kewalramani Reshma C-suite SELL 10b5-1 $116K ↗ EDGAR
2026-02-27 Kewalramani Reshma C-suite SELL 10b5-1 $1.2M ↗ EDGAR

Combined timeline — Congress & insiders

Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.

DateWhoTypeSize
Congress 2026-08-26 David Taylor SELL $1K–$15K
◆ insider 2026-07-02 McKechnie Duncan C-suite 10b5-1 SELL $800K
◆ insider 2026-07-02 Tatsis Ourania C-suite 10b5-1 SELL $787K
◆ insider 2026-07-01 Liu Joy C-suite 10b5-1 SELL $416K
◆ insider 2026-06-26 Bozic Carmen Other 10b5-1 SELL $288K
◆ insider 2026-06-18 Bozic Carmen Other 10b5-1 SELL $471K
◆ insider 2026-06-15 Bozic Carmen Other 10b5-1 SELL $1.8M
◆ insider 2026-06-05 Bozic Carmen Other 10b5-1 SELL $785K
◆ insider 2026-06-01 Liu Joy C-suite 10b5-1 SELL $364K
◆ insider 2026-05-29 Bozic Carmen Other 10b5-1 SELL $888K
◆ insider 2026-05-15 Bozic Carmen Other 10b5-1 SELL $614K
◆ insider 2026-05-15 Bunnage Mark E. C-suite 10b5-1 SELL $15K
◆ insider 2026-05-12 Bozic Carmen Other 10b5-1 SELL $3.1M
◆ insider 2026-05-04 Bhatia Sangeeta N. Director 10b5-1 SELL $135K
◆ insider 2026-05-01 Liu Joy C-suite 10b5-1 SELL $469K
◆ insider 2026-04-01 Liu Joy C-suite 10b5-1 SELL $439K
Congress 2026-03-27 Alan Armstrong BUY $1K–$15K
◆ insider 2026-03-27 Bozic Carmen Other 10b5-1 SELL $1.1M
◆ insider 2026-03-13 Bozic Carmen Other 10b5-1 SELL $1.1M
◆ insider 2026-03-11 McKechnie Duncan C-suite 10b5-1 SELL $1.3M
◆ insider 2026-03-04 McKechnie Duncan C-suite 10b5-1 SELL $1.2M
◆ insider 2026-03-02 Liu Joy C-suite 10b5-1 SELL $442K
◆ insider 2026-02-27 Bozic Carmen Other 10b5-1 SELL $1.1M
◆ insider 2026-02-27 Kewalramani Reshma C-suite 10b5-1 SELL $192K

FAQ Common questions

How much has Congress traded VRTX?

13 disclosed buys and 18 sells of VRTX (Vertex Pharmaceuticals Inc. / Ma) appear in official congressional financial disclosures.

Is it legal for members of Congress to trade VRTX?

Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.